This Article Abstract Full Text (PDF) All Versions of this Article: 147/12/5542    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Norman, A. W. Search for Related Content PubMed PubMed Citation Articles by Norman, A. W.

Vitamin D Receptor: New Assignments for an Already Busy Receptor

Department of Biochemistry and Biomedical Sciences, University of California, Riverside, California 92521

Address all correspondence and requests for reprints to: Dr. Anthony W. Norman, Department of Biochemistry, University of California, Riverside, California 92506. E-mail: Anthony.norman{at}ucr.edu.

	Abstract

Top Abstract References

 
With its discovery in 1920, the molecule vitamin D achieved prominence as a nutritionally essential vitamin important for calcium homeostasis, particularly in the intestine and bone. Then in 1932, the elucidation of vitamin D’s chemical structure revealed that this vitamin was in fact a steroid. But it was not until the late 1960s that it was appreciated that the steroid vitamin D was a precursor of a new steroid hormone, 1,25(OH)₂-vitamin D₃ [1,25(OH)₂D₃], that is produced by the kidney acting as an endocrine gland. The discovery in 1969 of the nuclear vitamin D receptor (VDR) for 1,25(OH)₂D₃ initiated a two-decade-long proliferation of reports that collectively described the broad sphere of influence of the vitamin D endocrine system that is defined by the presence of the VDR in over 30 tissue/organs of man. The new genomic frontiers defined by the cellular presence of the VDR include the immune system’s B and T lymphocytes, hair follicle, muscle, adipose tissue, bone marrow, and cancer cells. Unexpectedly in the mid 1980s, a new world of 1,25(OH)₂D₃-mediated rapid responses (RR) was discovered. These were responses that occurred too rapidly (minutes to an hour) to be explained as the simple consequence of the nuclear VDR regulating gene transcription. Some RR examples include the rapid intestinal absorption of calcium (transcaltachia), secretion of insulin by pancreatic ß-cells, opening of voltage-gated Ca²⁺ and Cl^– channels in osteoblasts, and the rapid migration of endothelial cells. The question then arose as to whether there was a second receptor, apart from the nuclear VDR, which responded to the presence of 1,25(OH)₂D₃ to generate RR? After some false starts, it now appears that the classic VDR, long known to reside in the cell nucleus, in some cells is also associated with caveolae present in the plasma membrane. Furthermore, the chemical properties of the conformationally flexible 1,25(OH)₂D₃ allow it to generate different shaped ligands for the VDR that are selective either for genomic or for RR. This minireview summarizes a proposed conformational ensemble model of the VDR that provides insight into how different ligand shapes of 1,25(OH)₂D₃ acting through the VDR in different cellular locations can selectively mediate both genomic and RR.

STEROID HORMONES ARE able to serve as chemical messengers in a wide number of species and target tissues to transmit signals that result in both genomic and rapid responses (RR). The ability of steroid hormones, including 1,25(OH)₂-vitamin D₃ [1,25(OH)₂D₃], to generate biological responses is defined by the presence of their cognate receptors in selected target organs and tissues. Although it is clear that steroid hormones’ genomic responses are mediated by formation of a ligand-receptor complex with the cognate receptor of the superfamily of steroid hormone nuclear receptors (1), new evidence indicates for all steroid hormones that their RR are mediated by a variety of receptor types located near or associated with the plasma membrane or its caveolae components (2). The time required for onset of the RR is system dependent and can vary from seconds (e.g. opening ion channels) to 10–60 min (e.g. activation of phosphatidylinositol-3'-kinase or endothelial nitric oxide synthase). This contrasts with genomic responses, which generally take a few hours to days to become fully manifest and which can be blocked by inhibitors of transcription and translation.

1,25(OH)₂D₃, which is a conformationally flexible molecule, is known to stimulate a wide array of RR; some examples include the rapid intestinal absorption of Ca²⁺ (transcaltachia), secretion of insulin by pancreatic ß-cells, opening of voltage-gated Ca²⁺ and Cl^– channels in osteoblasts, and the rapid migration of endothelial cells (2, 3). Intriguingly, one shape of 1,25(OH)₂D₃ is used for genomic responses, and a different shape serves as an agonist of RR (4). The question then arose as to whether there was a second receptor, apart from the nuclear vitamin D receptor (VDR), which responded to the presence of a different shaped 1,25(OH)₂D₃ to generate RR? The purpose of this minireview is to evaluate the VDR with respect to its involvement in genomic responses and then to review evidence that the same VDR is also involved in mediation of RR.

It has been generally assumed for receptor-ligand interactions that the ligand is frozen in a single conformation dictated by both the structural constraints of the ligand and the three-dimensional architecture of the peptide chains that create the ligand binding domain (LBD) of the receptor(s). The ligands for the thyroid receptor (T₃), the retinoic acid receptor (retinoic acid), and the VDR are all conformationally flexible, and the x-ray crystallographic structure for each receptor indicates that only one definitive conformer was present in each LBD (2). This clearly demonstrates that steroid receptors can capture one ligand conformation from a very large population of flexible conformers.

Figure 1, A–C, summarizes the three structural features of 1,25(OH)₂D₃ that empower its exceptional flexibility and as a consequence define its ability to generate a multitude of different agonist shapes for the VDR and other putative receptors. Figure 1, E and F, illustrates the shape of the optimal ligand for VDR-mediated nuclear responses and for RR as well for a second protein of the vitamin D endocrine system, the plasma transport protein, or vitamin D binding protein (DBP), the x-ray structure of which has also been elucidated. It is clear that the VDR, DBP, and the receptor for 1,25(OH)₂D₃-mediated RR each have a characteristic ligand shape. As a consequence, it may be possible to chemically synthesize analogs of 1,25(OH)₂D₃ that are selective for genomic responses or RR.

View larger version (32K): [in this window] [in a new window]   FIG. 1. The complex world of structural aspects of 1,25(OH)2D3. A, Structure of 1,25(OH)2D3 and identification of the three structural aspects of vitamin D seco-steroids that contribute to the conformational flexibility of this class of molecules. The side chain, because of the five single carbon-carbon bonds (indicated by the five arrows), is very conformationally flexible. B, The cyclohexane-like A-ring is free to interchange rapidly, millions of times per second, between a pair of chair-chair conformers effectively equilibrating the key 1- and 3ß-hydroxyls between equatorial and axial orientations. Thus, when the 1-hydroxyl is axial, the 3ß-hydroxyl is equatorial, and vice versa. C, Rotational freedom about the 6–7 carbon-carbon single bond of the seco B-ring allows conformations ranging from the open and extended 6-s-trans conformation, used by the VDR for genomic responses, to the more steroid-like 6-s-cis form of the hormone believed to be used by the VDR for RR. The inset box provides the structure of the 6-s-cis locked JN, which is of equivalent potency to 1,25(OH)2D3 in mediating RR. D, Structure of JN, which is chemically locked in a permanent 6-s-cis shape and has potency equivalent to 1,25(OH)2D3 in mediating RR (see Table 2 and text). E and F, Space-filling (E) and stick (F) representations illustrating the clear differences in the shapes of the three optimal ligands for the nuclear localized VDR (left), the membrane-caveolae localized VDR (middle), and the plasma DBP (right). The nuclear VDR ligand [1,25(OH)2D3] is in a bowl-shaped twisted 6-s-trans conformation with the A-ring and side chain both 30° above the plane of the C/D-ring. The relatively planar 6-s-cis locked JN is a ligand for the membrane VDR. The DBP ligand [25(OH)D3] is in a twisted 6-s-trans orientation with the A-ring C10–C19 exocyclic alkene 30° below the plane of the C/D-ring and the side chain almost 90° below the C/D-ring plane. Each of the illustrated molecules has its 25-OH pointed to the right and the A-ring to the left. The shapes of the nuclear VDR (29 ) and DBP (34 ) ligands were learned from the separate determination of the x-ray structure of each protein, whereas the shape of the membrane VDR ligand was determined by computer modeling.

View this table: [in this window] [in a new window]   TABLE 1. 1,25(OH)2D3 structure-function analysis of rapid responses

The current view of this laboratory is that transcaltachia and many other 1,25(OH)₂D₃-mediated RR are initiated by a membrane-localized receptor that binds 1,25(OH)₂D₃ (7). Recent work in our laboratory has focused on isolation of the intestinal, kidney, or lung membrane fractions that contains caveolae. Caveolae are flask-shaped membrane invaginations that are enriched in the sphingolipids and cholesterol commonly found in both caveolae and/or lipid rafts (8). The caveolae-enriched membrane fraction is isolated from chick or rat intestine, kidney, or lung tissue by Percoll buoyant density centrifugation. We find under both in vivo and in vitro conditions that there is a saturable binding of high-specific-activity tritiated 1,25(OH)₂D₃ in the caveolae-enriched membrane fraction. This binding activity is steroid specific for 1-hydroxylated analogs and for 1,25(OH)₂D₃ has a distribution constant (K_d) equal to 1.4 nM, which is identical to the nuclear VDR K_d for 1,25(OH)₂D₃ (7). Furthermore, by confocal microscopy, we showed that green fluorescent labeled antibodies to the classical nuclear VDR colocalized with red fluorescent labeled antibodies to caveolin-1 in caveolae present in the plasma membrane of ROS-17.2,8 osteoblast cells (7).

Both the author’s laboratory (7) and that of Lieberherr and Garabedian (9) have separately concluded that the RR effects of 1,25(OH)₂D₃ require a functional VDR. We found that in VDR-knockout mice (VDR-KO), 1,25(OH)₂D₃ was unable to stimulate the opening of voltage-gated Ca²⁺ and Cl^– channels (7, 10) and that there was a loss of 70–90% in the ability of [³H]1,25(OH)₂D₃ to bind to isolated caveolae membrane fractions obtained from VDR-KO intestine, lung, and kidney tissues (7). The residual binding of [³H]1,25(OH)₂D₃ present in VDR-KO tissues was found to be attributable to the presence of a truncated form of the VDR present in the strain of VDR-KO mice employed in our studies (10). Lieberherr and Garabedian found that in fibroblasts obtained from a patient with the genetic disease of vitamin D-resistant rickets, a single point mutation in the VDR (Lys45Glu) resulted in the loss of 1,25(OH)₂D₃ RR (9).

Thus, this laboratory’s view is that the classical VDR normally associated with the cell nucleus and gene transcription can also be resident near to or associated with caveolae present in the plasma membrane. It has also been reported that the estrogen receptor and androgen receptor are associated with caveolae of (2).

It is apparent that for the VDR there is a perceived problem, because a 6-s-trans shape of 1,25(OH)₂D₃ is obligatory for genomic responses, whereas a 6-s-cis shape is required for RR. This then poses the conundrum as to how a receptor with one LBD can bind ligands of quite different shapes to generate two quite different biological outcomes? Yet, the x-ray structure of the VDR revealed only one LBD, that which bound the 6-s-trans shape (see Fig. 1E).

One possible solution to the conundrum was obtained from molecular modeling of the VDR (11). Using the atomic coordinates of the x-ray structures of the VDR and computer modeling (see Fig. 2A), we have been able to identify the presence of a putative alternative LBD in the VDR that can accommodate via computer docking either the appropriate natural hormone or analogs that are known to be agonists only for RR (see Fig. 2A) (11). Figure 2A illustrates for the VDR the classical nuclear ligand pocket (red) and the proposed alternative ligand pocket (blue). Each ligand pocket is envisioned to have separate portals. The entrance to the nuclear pocket is dependent upon helix 12 being in an open configuration so that the hormone/ligand can enter into the LBD pocket and gain access to integral H-bonding residues thereby fully occupying the genomic pocket. Next, helix 12 moves to reclose the portal. The surprising discovery is that the alternative pocket and the genomic pocket overlap. Each of these pockets uses the same hydrogen-bonding partners of the VDR to stabilize the A-rings of the bound ligands; however, the remaining interactions of the C/D-ring and side chain of the ligand in the genomic or alternative pockets are entirely unique. Although the K_d of the genomic pocket is known from equilibrium binding experiments with [³H]1,25(OH)₂D₃ to be approximately 1.4 nM (7), it is possible that the alternative pocket may have a different K_d. In general, the effective doses of 1,25(OH)₂D₃ required to initiate RR have been found to be in the range of 1–10 nM.

View larger version (31K): [in this window] [in a new window]   FIG. 2. Structural details of the VDR that support a conformational ensemble model. A, Details of the LBD in the ribbon structures of the nuclear VDR: X, differences in the volume and shape of the interior of the VDR LBD (light blue) with the structure of the 1,25(OH)2D3 shown in wire-frame as revealed by x-ray crystallography of the protein plus ligand; Y, illustration for the VDR of the location of the classic genomic pocket (red: 1,25(OH)2-vitamin D3, a genomic agonist) and a putative alternative pocket (blue: 1,25(OH)2-lumisterol, a nongenomic 6-s-cis locked agonist) as studied by molecular modeling. Helix 12 (H12) is colored brown and shown in the closed conformation. The proposed alternative pocket portal lies between the C terminus of H1 and N terminus of H3. An intriguing aspect of the two ligand binding pocket model is that the A-ring of ligands bound to either the genomic pocket or alternative pocket use the same hydrogen-bonding partners (R274, S237, and S278) to stabilize their 1- and 3ß-hydroxyls. The conserved helix 5 R274 is shown in Corey Pauling (CPK) space filling model; thus, the VDR cannot bind two ligands simultaneously. Details of the modeling are provided in Refs. 2 and 11 . B, Schematic model of a receptor ensemble model to describe how a classic steroid receptor could accommodate differently shaped ligands that result in the initiation of either RR or genomic responses. The ensemble model proposes that there is a population of three different unoccupied receptor species (a, b, and c) illustrated by different positions of helix 12 (H12; colored brown) that are in rapid equilibrium with one another; each receptor conformer species may preferentially bind differently shaped ligands (35 ). In this example, transient occupancy of the alternative pocket by a ligand could/would lead to initiation of RR, whereas occupancy of the classical pocket by a ligand would lead to activation of genomic responses; both of these pockets are illustrated for the VDR in A. The alternative pocket is accessible in all three H12 conformers (a, b, and c). Occupancy of this alternative pocket is favored before achieving the steady-state equilibrium only for the receptor’s natural ligands given the increased accessibility coupled with weaker van der Waals interactions compared with genomic pocket occupancy. Receptor conformer (c) is the only conformer able to accept ligands that can bind to the classical ligand binding site leading to genomic responses because in conformers a and b, H12 blocks ligand accessibility to the conserved H5 Arg residue located at the innermost part of the classic ligand binding pocket. An interesting consequence of the receptor ensemble concept may be that association of the nuclear receptor with caveolae or cell membranes may change the ligand binding preferences to favor the alternative pocket. Ligand occupancy of this genomic pocket is favored under steady-state conditions because of the increase in thermodynamic stability derived from hydrophobic interactions. It is possible that drug analogs, especially those related to the natural hormone(s), may have differential fractional occupancies of the two pockets, thus affecting the efficiency of the cellular signaling pathways mediated by either pocket.

Figure 3 is a summary figure that integrates the signal transduction pathways that are used by the nuclear VDR and the membrane-associated VDR using 1,25(OH)₂D₃ as a conformationally flexible agonist. This model emphasizes the complexity of overlapping and interconnecting signal transduction pathways. Although there is a solid and secure foundation describing 1,25(OH)₂D₃-mediated genomic actions, 1,25(OH)₂D₃-mediated RR are still in their developmental phase. One extraordinary challenge will be to identify and fully biochemically characterize the membrane-associated VDR. An equally daunting task will be to define in the various cell systems that display RR the identification of the specific signal transduction pathways that contribute to mediation of a specific rapid biological response. An additional important question is whether the membrane VDR can communicate with the nucleus of the cell to modulate gene transcription. In data not shown, but summarized in Fig. 3, there are at least five different systems where molecular biological evidence has been obtained for the process of cross-talk from 1,25(OH)₂D₃ RR to changes in gene expression in the cell nucleus. In these studies, 6-s-cis locked analogs have been shown to modulate genomic responses at relatively early time intervals (2–4 h). Without a doubt, it is clear that the already busy genomic oriented VDR has new assignments in the realm of 1,25(OH)₂D₃-mediated RR.

View larger version (39K): [in this window] [in a new window]   FIG. 3. Schematic model describing how the conformationally flexible 1,25(OH)2D3 can interact with the VDR localized in the cell nucleus to generate genomic responses or in caveolae of the plasma membrane to generate RR. Binding of 1,25(OH)2D3 to the caveolae-associated VDR may result in the activation of one or more second messenger systems, including phospholipase C (PKC), protein kinase C, G protein-coupled receptors, or phosphatidylinositol-3'-kinase (PI3K). There are a number of possible outcomes including opening of the voltage-gated calcium or chloride channels or generation of the indicated second messengers. Some of these second messengers, particularly RAF/MAPK, may engage in cross-talk with the nucleus to modulate gene expression. PtdIns-3,4,5-P3, Phosphatidylinositol-3,4,5-trisphosphate.

	Acknowledgments

 
I thank Dr. Matt Mizwicki for his extensive computer modeling of the VDR ligand-binding domain and also Professor Helen Henry for a critical reading of this manuscript.

Received July 8, 2006. Accepted August 7, 2006.

	Footnotes

 
Work from the author’s laboratory has been supported by National Institutes of Health Grant DK-009012 for the past 39 yr.

Disclosure summary: The author has nothing to declare.

First Published Online August 31, 2006

Abbreviations: 1,25(OH)₂D₃, 1,25(OH)₂-vitamin D₃; DBP, vitamin D binding protein; JN, 1,25(OH)₂-lumisterol; KO, knockout; LBD, ligand binding domain; RR, rapid response(s); VDR, vitamin D receptor.

Received July 14, 2006.

Accepted for publication August 11, 2006.

	References

Top Abstract References

 

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily: the second decade. Cell 83:835–839[CrossRef][Medline]
2. Norman AW, Mizwicki MT, Norman DPG 2004 Steroid hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 3:27–41[CrossRef][Medline]
3. Norman AW 2005 1,25(OH)₂-Vitamin D₃ mediated rapid and genomic responses are dependent upon critical structure-function relationships for both the ligand and receptor(s). In: Feldman D, Pike JW, Glorieux FH, eds. Vitamin D. 2nd ed. San Diego: Elsevier Academic Press; 381–407
4. Norman AW, Okamura WH, Hammond MW, Bishop JE, Dormanen MC, Bouillon R, Van Baelen H, Ridall AL, Daane E, Khoury R, Farach-Carson MC 1997 Comparison of 6-s-cis and 6-s-trans locked analogs of 1,25(OH)₂-vitamin D₃ indicates that the 6-s-cis conformation is preferred for rapid nongenomic biological responses and that neither 6-s-cis nor 6-s-trans locked analogs are preferred for genomic biological responses. Mol Endocrinol 11:1518–1531[Abstract/Free Full Text]
5. Reichel H, Koeffler HP, Norman AW 1989 The role of the vitamin D endocrine system in health and disease. New Engl J Med 320:980–991[Medline]
6. Yoshimoto Y, Nemere I, Norman AW 1986 Hypercalcemia inhibits the "rapid" stimulatory effect on calcium transport in perfused duodena from normal chicks mediated by 1,25-dihydroxyvitamin D. Endocrinology 118:2300–2304[Abstract]
7. Huhtakangas JA, Olivera CJ, Bishop JE, Zanello LP, Norman AW 2004 The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1,25(OH)₂-vitamin D₃ in vivo and in vitro. Mol Endocrinol 18:2660–2671[Abstract/Free Full Text]
8. Razani B, Woodman SE, Lisanti MP 2002 Caveolae: from cell biology to animal physiology. Pharmacol Rev 54:431–467[Abstract/Free Full Text]
9. Nguyen TM, Lieberherr M, Fritsch J, Guillozo H, Alvarez ML, Fitouri Z, Jehan F, Garabedian M 2004 The rapid effects of 1,25-(OH)₂D₃ require the VDR and influence 24-hydroxylate activity: studies in human skin fibroblasts bearing vitamin D receptor mutations. J Biol Chem 279:7591–7597[Abstract/Free Full Text]
10. Bula CM, Huhtakangas J, Olivera C, Bishop JE, Norman AW, Henry HL 2005 Presence of a truncated form of the vitamin D receptor (VDR) in a strain of VDR-knockout mice. Endocrinology 146:5581–5586[Abstract/Free Full Text]
11. Mizwicki MT, Keidel D, Bula CM, Bishop JE, Zanello LP, Wurtz JM, Moras D, Norman AW 2004 Identification of an alternative ligand-binding pocket in the nuclear vitamin D receptor and its functional importance in 1,25(OH)₂-vitamin D₃ signaling. Proc Natl Acad Sci USA 101:12876–12881[Abstract/Free Full Text]
12. Kousteni S, Bellido T, Plotkin LI, O’Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC 2001 Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104:719–730[Medline]
13. Zanello LP, Norman AW 1997 Stimulation by 1,25(OH)₂-vitamin D₃ of whole cell chloride currents in osteoblastic ROS 17/2.8 cells: a structure-function study. J Biol Chem 272:22617–22622[Abstract/Free Full Text]
14. Kajikawa M, Ishida H, Fujimoto S, Mukai E, Nishimura M, Fujita J, Tsuura Y, Okamoto Y, Norman AW, Seino Y 1999 An insulinotropic effect of vitamin D analog with increasing intracellular Ca²⁺ concentration in pancreatic ß-cells through nongenomic signal transduction. Endocrinology 140:4706–4712[Abstract/Free Full Text]
15. Rebsamen MC, Sun J, Norman AW, Liao JK 2002 1,25-Dihydroxyvitamin D₃ induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 91:17–24[Abstract/Free Full Text]
16. Haussler MR, Myrtle JF, Norman AW 1968 The association of a metabolite of vitamin D₃ with intestinal mucosa chromatin, in vivo. J Biol Chem 243:4055–4064[Abstract/Free Full Text]
17. Myrtle JF, Haussler MR, Norman AW 1970 Evidence for the biologically active form of cholecalciferol in the intestine. J Biol Chem 245:1190–1196[Abstract/Free Full Text]
18. Norman AW, Myrtle JF, Midgett RJ, Nowicki HG, Williams V, Popjak G 1971 1,25-Dihydroxycholecalciferol: identification of the proposed active form of vitamin D₃ in the intestine. Science 173:51–54[Abstract/Free Full Text]
19. Haussler MR, Norman AW 1969 Chromosomal receptor for a vitamin D metabolite. Proc Natl Acad Sci USA 62:155–162[Abstract/Free Full Text]
20. Tsai HC, Norman AW 1973 Studies on the mode of action of calciferol. VI. Effect of 1,25-dihydroxyvitamin D₃ on RNA synthesis in the intestinal mucosa. Biochem Biophys Res Commun 54:622–627[CrossRef][Medline]
21. Norman AW 1965 Actinomycin D and the response to vitamin D. Science 149:184–186[Abstract/Free Full Text]
22. Tsai HC, Midgett RJ, Norman AW 1973 Studies on calciferol metabolism.VII. The effects of actinomycin D and cycloheximide on the metabolism, tissue and subcellular localization, and action of vitamin D3. Arch Biochem Biophys 157:339–347[CrossRef][Medline]
23. Walters MR, Hunziker W, Norman AW 1980 Unoccupied 1,25-dihydroxyvitamin D₃ receptors: nuclear/cytosol ratio depends on ionic strength. J Biol Chem 255:6799–6805[Free Full Text]
24. Okamura WH, Norman AW, Wing RM 1974 Vitamin D: concerning the relationship between molecular topology and biological function. Proc Natl Acad Sci USA 71:4194–4197[Abstract/Free Full Text]
25. Wing RM, Okamura WH, Pirio MR, Sine SM, Norman AW 1974 Vitamin D₃: conformations of vitamin D₃, 1,25-dihydroxyvitamin D₃, and dihydrotachysterol₃. Science 186:939–941[Abstract/Free Full Text]
26. Nemere I, Yoshimoto Y, Norman AW 1984 Calcium transport in perfused duodena from normal chicks: enhancement within fourteen minutes of exposure to 1,25-dihydroxyvitamin D₃. Endocrinology 115:1476–1483[Abstract]
27. Norman AW, Roth J, Orci L 1982 The vitamin D endocrine system: Steroid metabolism, hormone receptors and biological response (calcium binding proteins). Endocr Rev 3:331–366[CrossRef][Medline]
28. Nemere I, Dormanen MC, Hammond MW, Okamura WH, Norman AW 1994 Identification of a specific binding protein for 1,25-dihydroxyvitamin D₃ in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J Biol Chem 269:23750–23756[Abstract/Free Full Text]
29. Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D 2000 The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 5:173–179[CrossRef][Medline]
30. Mizwicki MT, Bishop JE, Olivera CJ, Huhtakangas JA, Norman AW 2003 Evidence that annexin II is not a putative membrane receptor for 1,25(OH)₂-vitamin D₃. J Cell Biochem 91:852–863
31. Norman AW, Olivera CJ, Barreto Silva FR, Bishop JE 2002 A specific binding protein/receptor for 1,25-dihydroxy D₃ is present in an intestinal caveolae membrane fraction. Biochem Biophys Res Commun 298:414–419[CrossRef][Medline]
32. Nemere I, Farach-Carson MC, Rohe B, Sterling TM, Norman AW, Boyan BD, Safford SE 2004 Ribozyme knockdown functionally links a 1,25(OH)₂D₃ membrane binding protein (1,25D₃-MARRS) and phosphate uptake in intestinal cells. Proc Natl Acad Sci USA 101:7392–7397[Abstract/Free Full Text]
33. Zanello LP, Norman AW 2004 Rapid modulation of osteoblast ion channel responses by 1,25(OH)₂-vitamin D₃ requires the presence of a functional vitamin D nuclear receptor. Proc Natl Acad Sci USA 101:1589–1594[Abstract/Free Full Text]
34. Verboven C, Rabijns A, De Maeyer M, Van Baelen H, Bouillon R, De Ranter C 2002 A structural basis for the unique binding features of the human vitamin D-binding protein. Nat Struct Biol 9:131–136[CrossRef][Medline]
35. Bursavich MG, Rich DH 2002 Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. J Med Chem 45:541–558[CrossRef][Medline]

This article has been cited by other articles:

				J. C. McCann and B. N. Ames Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J, April 1, 2008; 22(4): 982 - 1001. [Abstract] [Full Text] [PDF]

				D. X. Tishkoff, K. A. Nibbelink, K. H. Holmberg, L. Dandu, and R. U. Simpson Functional Vitamin D Receptor (VDR) in the T-Tubules of Cardiac Myocytes: VDR Knockout Cardiomyocyte Contractility Endocrinology, February 1, 2008; 149(2): 558 - 564. [Abstract] [Full Text] [PDF]

				H. J. Lee, Y. Ji, S. Paul, H. Maehr, M. Uskokovic, and N. Suh Activation of Bone Morphogenetic Protein Signaling by a Gemini Vitamin D3 Analogue Is Mediated by Ras/Protein Kinase C{alpha} Cancer Res., December 15, 2007; 67(24): 11840 - 11847. [Abstract] [Full Text] [PDF]

				M. L. Slattery, J. Herrick, R. K. Wolff, B. J. Caan, J. D. Potter, and C. Sweeney CDX2 VDR Polymorphism and Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2752 - 2755. [Abstract] [Full Text] [PDF]

				S. R. Hammes and E. R. Levin Extranuclear Steroid Receptors: Nature and Actions Endocr. Rev., December 1, 2007; 28(7): 726 - 741. [Abstract] [Full Text] [PDF]

				E. K.-H. Chow, B. Razani, and G. Cheng Innate immune system regulation of nuclear hormone receptors in metabolic diseases J. Leukoc. Biol., August 1, 2007; 82(2): 187 - 195. [Abstract] [Full Text] [PDF]

				E J Lock, R Ornsrud, L Aksnes, F A T Spanings, R Waagbo, and G Flik The vitamin D receptor and its ligand 1{alpha},25-dihydroxyvitamin D3 in Atlantic salmon (Salmo salar) J. Endocrinol., June 1, 2007; 193(3): 459 - 471. [Abstract] [Full Text] [PDF]

				S.D. Crowley, S.B. Gurley, M.J. Herrera, P. Ruiz, R. Griffiths, A.P. Kumar, H.-S. Kim, O. Smithies, T.H. Le, T.M. Coffman, et al. Role of Renal Angiotensin II Type 1 Receptors in the Genesis of Hypertension: Guyton Revisited: Angiotensin II Causes Hypertension and Cardiac Hypertrophy through Its Receptors in the Kidney. Proc Natl Acad Sci U S A 103: 17985-17990, 2006 J. Am. Soc. Nephrol., February 1, 2007; 18(2): 356 - 363. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 147/12/5542    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Norman, A. W. Search for Related Content PubMed PubMed Citation Articles by Norman, A. W.